Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 33 entries
Sorted by: Best Match Show Resources per page
Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities.

Nature communications

Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, Brillet R, Cala O, Douguet D, Bourguet W, Krimm I, Pawlotsky JM, Guichou JF.
PMID: 27652979
Nat Commun. 2016 Sep 22;7:12777. doi: 10.1038/ncomms12777.

Cyclophilins are peptidyl-prolyl cis/trans isomerases (PPIase) that catalyse the interconversion of the peptide bond at proline residues. Several cyclophilins play a pivotal role in the life cycle of a number of viruses. The existing cyclophilin inhibitors, all derived from...

Cite
Ahmed-Belkacem A, Colliandre L, Ahnou N, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016;7:12777doi: 10.1038/ncomms12777.
Ahmed-Belkacem, A., Colliandre, L., Ahnou, N., Nevers, Q., Gelin, M., Bessin, Y., Brillet, R., Cala, O., Douguet, D., Bourguet, W., Krimm, I., Pawlotsky, J. M., & Guichou, J. F. (2016). Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nature communications, 712777. https://doi.org/10.1038/ncomms12777
Ahmed-Belkacem, Abdelhakim, et al. "Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities." Nature communications vol. 7 (2016): 12777. doi: https://doi.org/10.1038/ncomms12777
Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, Brillet R, Cala O, Douguet D, Bourguet W, Krimm I, Pawlotsky JM, Guichou JF. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016 Sep 22;7:12777. doi: 10.1038/ncomms12777. PMID: 27652979; PMCID: PMC5036131.
Copy Download .nbib Format: NLM
Mirizzi's syndrome--results from a large western experience.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Gomez D, Rahman SH, Toogood GJ, Prasad KR, Lodge JP, Guillou PJ, Menon KV.
PMID: 18333104
HPB (Oxford). 2006;8(6):474-9. doi: 10.1080/13651820600840082.

BACKGROUND: This paper reports a series of patients with Mirizzi's syndrome (MS) who were managed at our institution over an 11-year (1994-2005) period.METHODS: Retrospective case note study of patients with a definitive or possible diagnosis of MS stated in...

Cite
Gomez D, Rahman SH, Toogood GJ, et al. Mirizzi's syndrome--results from a large western experience. HPB (Oxford). 2006;8(6):474-9doi: 10.1080/13651820600840082.
Gomez, D., Rahman, S. H., Toogood, G. J., Prasad, K. R., Lodge, J. P., Guillou, P. J., & Menon, K. V. (2006). Mirizzi's syndrome--results from a large western experience. HPB : the official journal of the International Hepato Pancreato Biliary Association, 8(6), 474-9. https://doi.org/10.1080/13651820600840082
Gomez, D, et al. "Mirizzi's syndrome--results from a large western experience." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 8,6 (2006): 474-9. doi: https://doi.org/10.1080/13651820600840082
Gomez D, Rahman SH, Toogood GJ, Prasad KR, Lodge JP, Guillou PJ, Menon KV. Mirizzi's syndrome--results from a large western experience. HPB (Oxford). 2006;8(6):474-9. doi: 10.1080/13651820600840082. PMID: 18333104; PMCID: PMC2020759.
Copy Download .nbib Format: NLM
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells.

Cancers

Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H.
PMID: 24216980
Cancers (Basel). 2013 Apr 03;5(2):334-56. doi: 10.3390/cancers5020334.

The epithelial to mesenchymal transition (EMT) enables epithelial cells with a migratory mesenchymal phenotype. It is activated in cancer cells and is involved in invasion, metastasis and stem-like properties. ZEB1, an E-box binding transcription factor, is a major suppressor...

Cite
Roche J, Nasarre P, Gemmill R, et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel). 2013;5(2):334-56doi: 10.3390/cancers5020334.
Roche, J., Nasarre, P., Gemmill, R., Baldys, A., Pontis, J., Korch, C., Guilhot, J., Ait-Si-Ali, S., & Drabkin, H. (2013). Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 5(2), 334-56. https://doi.org/10.3390/cancers5020334
Roche, Joëlle, et al. "Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells." Cancers vol. 5,2 (2013): 334-56. doi: https://doi.org/10.3390/cancers5020334
Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel). 2013 Apr 03;5(2):334-56. doi: 10.3390/cancers5020334. PMID: 24216980; PMCID: PMC3730320.
Copy Download .nbib Format: NLM
Fragment and conquer: from structure to complexes to function.

Structure (London, England : 1993)

Guichou JF, Labesse G.
PMID: 23063007
Structure. 2012 Oct 10;20(10):1617-9. doi: 10.1016/j.str.2012.09.008.

In this issue of Structure, Shumilin and colleagues show the power of metabolite screening by means of X-ray crystallography to link an orphan protein domain with an orphan biochemical function. This result paves the way for large-scale functional annotation...

Cite
Guichou JF, Labesse G. Fragment and conquer: from structure to complexes to function. Structure. 2012;20(10):1617-9doi: 10.1016/j.str.2012.09.008.
Guichou, J. F., & Labesse, G. (2012). Fragment and conquer: from structure to complexes to function. Structure (London, England : 1993), 20(10), 1617-9. https://doi.org/10.1016/j.str.2012.09.008
Guichou, Jean-François, and Labesse, Gilles. "Fragment and conquer: from structure to complexes to function." Structure (London, England : 1993) vol. 20,10 (2012): 1617-9. doi: https://doi.org/10.1016/j.str.2012.09.008
Guichou JF, Labesse G. Fragment and conquer: from structure to complexes to function. Structure. 2012 Oct 10;20(10):1617-9. doi: 10.1016/j.str.2012.09.008. PMID: 23063007.
Copy Download .nbib Format: NLM
Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Sarela AI, Gallagher HJ, Macadam RC, O'Riordain DS, Parkin A, Guillou PJ.
PMID: 23578153
Colorectal Dis. 2000 Nov 17;2(6):346-50. doi: 10.1046/j.1463-1318.2000.00162.x.

OBJECTIVE: The hepatic perfusion index (HPI) is a ratio of the gradient of hepatic arterial to total hepatic blood flow. This study correlated HPI with histopathological indicators of prognosis and disease-free survival following curative resection of colorectal cancer.PATIENTS AND...

Cite
Sarela AI, Gallagher HJ, Macadam RC, et al. Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma. Colorectal Dis. 2000;2(6):346-50doi: 10.1046/j.1463-1318.2000.00162.x.
Sarela, A. I., Gallagher, H. J., Macadam, R. C., O'Riordain, D. S., Parkin, A., & Guillou, P. J. (2000). Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2(6), 346-50. https://doi.org/10.1046/j.1463-1318.2000.00162.x
Sarela, A I, et al. "Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma." Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland vol. 2,6 (2000): 346-50. doi: https://doi.org/10.1046/j.1463-1318.2000.00162.x
Sarela AI, Gallagher HJ, Macadam RC, O'Riordain DS, Parkin A, Guillou PJ. Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma. Colorectal Dis. 2000 Nov 17;2(6):346-50. doi: 10.1046/j.1463-1318.2000.00162.x. PMID: 23578153.
Copy Download .nbib Format: NLM
Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface.

Cancers

Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, Allemand F, Guichou JF, Drucbert AS, Foulon C, Magnez R, Thuru X, Corvaisier M, Huet G, Chavatte P, Melnyk P, Bailly F, Cotelle P.
PMID: 29738494
Cancers (Basel). 2018 May 08;10(5). doi: 10.3390/cancers10050140.

Intrinsically disordered protein YAP (yes-associated protein) interacts with TEADs transcriptional factors family (transcriptional enhancer associated domain) creating three interfaces. Interface 3, between the Ω-loop of YAP and a shallow pocket of TEAD was identified as the most important TEAD...

Cite
Gibault F, Coevoet M, Sturbaut M, et al. Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface. Cancers (Basel). 2018;10(5)doi: 10.3390/cancers10050140.
Gibault, F., Coevoet, M., Sturbaut, M., Farce, A., Renault, N., Allemand, F., Guichou, J. F., Drucbert, A. S., Foulon, C., Magnez, R., Thuru, X., Corvaisier, M., Huet, G., Chavatte, P., Melnyk, P., Bailly, F., & Cotelle, P. (2018). Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface. Cancers, 10(5), . https://doi.org/10.3390/cancers10050140
Gibault, Floriane, et al. "Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface." Cancers vol. 10,5 (2018). doi: https://doi.org/10.3390/cancers10050140
Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, Allemand F, Guichou JF, Drucbert AS, Foulon C, Magnez R, Thuru X, Corvaisier M, Huet G, Chavatte P, Melnyk P, Bailly F, Cotelle P. Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface. Cancers (Basel). 2018 May 08;10(5). doi: 10.3390/cancers10050140. PMID: 29738494; PMCID: PMC5977113.
Copy Download .nbib Format: NLM
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.

British journal of haematology

Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, Legros L, Charbonnier A, Coiteux V, Dartigeas C, Escoffre-Barbe M, Roy L, Cony-Makhoul P, Dubruille V, Gardembas M, Huguet F, Réa D, Cayssials E, Guilhot F, Bergeron A, Molimard M, Mahon FX, Cayuela JM, Busque L, Bouchet S.
PMID: 34195988
Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30.

Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion (PlEff). We randomly evaluated whether therapeutic drug monitoring (TDM)...

Cite
Rousselot P, Mollica L, Guilhot J, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194(2):393-402doi: 10.1111/bjh.17654.
Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., Escoffre-Barbe, M., Roy, L., Cony-Makhoul, P., Dubruille, V., Gardembas, M., Huguet, F., Réa, D., Cayssials, E., Guilhot, F., Bergeron, A., Molimard, M., Mahon, F. X., Cayuela, J. M., Busque, L., & Bouchet, S. (2021). Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. British journal of haematology, 194(2), 393-402. https://doi.org/10.1111/bjh.17654
Rousselot, Philippe, et al. "Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients." British journal of haematology vol. 194,2 (2021): 393-402. doi: https://doi.org/10.1111/bjh.17654
Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, Legros L, Charbonnier A, Coiteux V, Dartigeas C, Escoffre-Barbe M, Roy L, Cony-Makhoul P, Dubruille V, Gardembas M, Huguet F, Réa D, Cayssials E, Guilhot F, Bergeron A, Molimard M, Mahon FX, Cayuela JM, Busque L, Bouchet S. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30. PMID: 34195988.
Copy Download .nbib Format: NLM
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with .

Clinical cancer research : an official journal of the American Association for Cancer Research

Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D.
PMID: 32859654
Clin Cancer Res. 2020 Dec 01;26(23):6242-6253. doi: 10.1158/1078-0432.CCR-20-1037. Epub 2020 Aug 28.

CONCLUSIONS: ctDNA sequencing is clinically relevant for the detection of

Cite
Ortiz-Cuaran S, Mezquita L, Swalduz A, et al. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with . Clin Cancer Res. 2020;26(23):6242-6253doi: 10.1158/1078-0432.CCR-20-1037.
Ortiz-Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M., Mazieres, J., Leonce, C., Jovelet, C., Pradines, A., Avrillon, V., Chumbi Flores, W. R., Lacroix, L., Loriot, Y., Westeel, V., Ngo-Camus, M., Tissot, C., Raynaud, C., Gervais, R., Brain, E., Monnet, I., Giroux Leprieur, E., Caramella, C., Mahier-Aït Oukhatar, C., Hoog-Labouret, N., de Kievit, F., Howarth, K., Morris, C., Green, E., Friboulet, L., Chabaud, S., Guichou, J. F., Perol, M., Besse, B., Blay, J. Y., Saintigny, P., & Planchard, D. (2020). Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with . Clinical cancer research : an official journal of the American Association for Cancer Research, 26(23), 6242-6253. https://doi.org/10.1158/1078-0432.CCR-20-1037
Ortiz-Cuaran, Sandra, et al. "Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,23 (2020): 6242-6253. doi: https://doi.org/10.1158/1078-0432.CCR-20-1037
Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with . Clin Cancer Res. 2020 Dec 01;26(23):6242-6253. doi: 10.1158/1078-0432.CCR-20-1037. Epub 2020 Aug 28. PMID: 32859654.
Copy Download .nbib Format: NLM
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A.
PMID: 29381150
Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30.

This corrects the article DOI: 10.1038/leu.2017.9.

Cite
Schütz C, Inselmann S, Saussele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2018;32(4):1054doi: 10.1038/leu.2017.348.
Schütz, C., Inselmann, S., Saussele, S., Dietz, C. T., Müller, M. C., Eigendorff, E., Brendel, C. A., Metzelder, S. K., Brümmendorf, T. H., Waller, C., Dengler, J., Goebeler, M. E., Herbst, R., Freunek, G., Hanzel, S., Illmer, T., Wang, Y., Lange, T., Finkernagel, F., Hehlmann, R., Huber, M., Neubauer, A., Hochhaus, A., Guilhot, J., Mahon, F. X., Pfirrmann, M., & Burchert, A. (2018). Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia, 32(4), 1054. https://doi.org/10.1038/leu.2017.348
Schütz, C, et al. "Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML." Leukemia vol. 32,4 (2018): 1054. doi: https://doi.org/10.1038/leu.2017.348
Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30. PMID: 29381150.
Copy Download .nbib Format: NLM
Nutritional and immunological assessment of patients with anorexia nervosa.

Clinical nutrition (Edinburgh, Scotland)

Dowd PS, Kelleher J, Walker BE, Guillou PJ.
PMID: 16829414
Clin Nutr. 1983 Jul;2(2):79-83. doi: 10.1016/0261-5614(83)90037-7.

The nutritional and immunological status of patients with anorexia nervosa was assessed. Anthropometric measurements were found to be lowered as were the serum levels of zinc (p

Cite
Dowd PS, Kelleher J, Walker BE, et al. Nutritional and immunological assessment of patients with anorexia nervosa. Clin Nutr. 1983;2(2):79-83doi: 10.1016/0261-5614(83)90037-7.
Dowd, P. S., Kelleher, J., Walker, B. E., & Guillou, P. J. (1983). Nutritional and immunological assessment of patients with anorexia nervosa. Clinical nutrition (Edinburgh, Scotland), 2(2), 79-83. https://doi.org/10.1016/0261-5614(83)90037-7
Dowd, P S, et al. "Nutritional and immunological assessment of patients with anorexia nervosa." Clinical nutrition (Edinburgh, Scotland) vol. 2,2 (1983): 79-83. doi: https://doi.org/10.1016/0261-5614(83)90037-7
Dowd PS, Kelleher J, Walker BE, Guillou PJ. Nutritional and immunological assessment of patients with anorexia nervosa. Clin Nutr. 1983 Jul;2(2):79-83. doi: 10.1016/0261-5614(83)90037-7. PMID: 16829414.
Copy Download .nbib Format: NLM
Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al.

Leukemia

Roy L, Guilhot J, Martineau G, Guilhot F.
PMID: 16281065
Leukemia. 2006 Jan;20(1):149. doi: 10.1038/sj.leu.2404027.

No abstract available.

Cite
Roy L, Guilhot J, Martineau G, et al. Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al. Leukemia. 2006;20(1):149doi: 10.1038/sj.leu.2404027.
Roy, L., Guilhot, J., Martineau, G., & Guilhot, F. (2006). Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al. Leukemia, 20(1), 149. https://doi.org/10.1038/sj.leu.2404027
Roy, L, et al. "Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al." Leukemia vol. 20,1 (2006): 149. doi: https://doi.org/10.1038/sj.leu.2404027
Roy L, Guilhot J, Martineau G, Guilhot F. Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al. Leukemia. 2006 Jan;20(1):149. doi: 10.1038/sj.leu.2404027. PMID: 16281065.
Copy Download .nbib Format: NLM
Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication.

Cell reports

Lahaye X, Satoh T, Gentili M, Cerboni S, Silvin A, Conrad C, Ahmed-Belkacem A, Rodriguez EC, Guichou JF, Bosquet N, Piel M, Le Grand R, King MC, Pawlotsky JM, Manel N.
PMID: 27149839
Cell Rep. 2016 Apr 26;15(4):879-892. doi: 10.1016/j.celrep.2016.03.074. Epub 2016 Apr 14.

During the early phase of replication, HIV reverse transcribes its RNA and crosses the nuclear envelope while escaping host antiviral defenses. The host factor Cyclophilin A (CypA) is essential for these steps and binds the HIV capsid; however, the...

Cite
Lahaye X, Satoh T, Gentili M, et al. Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep. 2016;15(4):879-892doi: 10.1016/j.celrep.2016.03.074.
Lahaye, X., Satoh, T., Gentili, M., Cerboni, S., Silvin, A., Conrad, C., Ahmed-Belkacem, A., Rodriguez, E. C., Guichou, J. F., Bosquet, N., Piel, M., Le Grand, R., King, M. C., Pawlotsky, J. M., & Manel, N. (2016). Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell reports, 15(4), 879-892. https://doi.org/10.1016/j.celrep.2016.03.074
Lahaye, Xavier, et al. "Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication." Cell reports vol. 15,4 (2016): 879-892. doi: https://doi.org/10.1016/j.celrep.2016.03.074
Lahaye X, Satoh T, Gentili M, Cerboni S, Silvin A, Conrad C, Ahmed-Belkacem A, Rodriguez EC, Guichou JF, Bosquet N, Piel M, Le Grand R, King MC, Pawlotsky JM, Manel N. Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep. 2016 Apr 26;15(4):879-892. doi: 10.1016/j.celrep.2016.03.074. Epub 2016 Apr 14. PMID: 27149839; PMCID: PMC4850421.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 33 entries